[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618337":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":25,"responsibleParty":36,"collaborators":25,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":25,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":25,"studyType":51,"phases":52,"briefSummary":43,"conditions":54,"keywords":56,"overallStatus":58,"whyStopped":25,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":25},{"fullName":5,"class":6},"Joincare Pharmaceutical Group Industry Co., Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR","Placebo Injection, SC",[13],"Other: Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"JKN2401 Injection","EXPERIMENTAL","JKN2401 Injection, SC dose A",[19],"Biological: JKN2401 Injection",[21,26],{"type":22,"name":15,"description":23,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","JKN2401 subcutaneous injection, Q4W",[15],null,{"type":27,"name":9,"description":28,"armGroupLabels":29,"otherNames":25},"OTHER","Placebo subcutaneous injection,Q4W",[9],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Ying Yang","CONTACT","+86-0755-33268688","overseas@joincare.com",{"type":37,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100618337","phase-3-a-phase-3-trial-of-jkn2401-injection-in-copd-100618337",false,"NCT07330310","A Phase 3 Trial of JKN2401 Injection in COPD","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous JKN2401 Injection in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)","Inclusion Criteria:\n\n* Written informed consent; able and willing to comply with study procedures.\n* Adults with documented COPD diagnosis and medical history consistent with guideline criteria.\n* Relevant exposure history consistent with COPD (e.g., smoking and\u002For biomass exposure).\n* On stable, guideline-based maintenance COPD therapy prior to randomization, per investigator judgment.\n* Protocol-defined exacerbation history, symptom burden, and lung function at screening.\n\nExclusion Criteria:\n\n* Current or past asthma, or other clinically significant respiratory disease that may confound assessment.\n* Clinically significant uncontrolled comorbidities that increase risk or interfere with participation\u002Foutcomes.\n* Immunodeficiency\u002Fimmune dysregulation, active autoimmune disease requiring systemic immunosuppression, or significant opportunistic infection history.\n* Active clinically significant infection or recent infection requiring systemic therapy; recent protocol-defined COPD exacerbation.\n* Current\u002Frecent malignancy (except low-risk, adequately treated cancers per protocol) or clinically significant abnormal screening labs.\n* Prohibited recent vaccines or therapies, prior relevant biologic\u002Ftargeted therapy exposure, severe hypersensitivity to biologics\u002FIMP, pregnancy\u002Fbreastfeeding, or inability to comply (including substance abuse), per investigator judgment.","ALL","40 Years","80 Years",{"count":49,"type":50},888,"ESTIMATED","INTERVENTIONAL",[53],"PHASE3",[55],"Chronic Obstructive Pulmonary Disease (COPD)",[57],"JKN2401","NOT_YET_RECRUITING","2026-01-12",{"date":61,"type":62},"2026-01-14","ACTUAL",{"date":64,"type":50},"2026-03",{"date":66,"type":50},"2027-11",{"name":5,"class":6}]